The Pauling Legacy and Why It Stuck
In 1970, biochemist Linus Pauling published "Vitamin C and the Common Cold," arguing that megadoses—2,000 mg to 10,000 mg daily—could prevent respiratory infections. The book sold millions. By the 1980s, high-dose vitamin C had become shorthand for cold prevention. Yet Pauling's own research methods were criticized for bias, and independent replication proved far messier than his promotional narrative suggested.
The legacy persists because the mechanistic story sounds plausible: vitamin C supports neutrophil function, reduces histamine in response to pathogens, and acts as an antioxidant during immune stress. But plausible mechanisms don't guarantee clinical outcomes. The question isn't whether vitamin C matters for immunity—it does. The question is whether megadosing prevents colds in otherwise healthy people.
Prophylactic vs. Therapeutic: Two Entirely Different Questions
This distinction matters more than most articles acknowledge. "Prophylactic" means preventing infection before exposure. "Therapeutic" means treating symptoms after infection begins. Vitamin C shows different efficacy in each scenario.
Pauling framed his hypothesis as prophylactic—take megadoses year-round to prevent colds. The evidence here is weak. A 2013 meta-analysis published in the Cochrane Database of Systematic Reviews (conducted by Hemilä and Chalker) examined 29 trials with 11,306 participants receiving continuous high-dose vitamin C supplementation. The result: vitamin C did not reduce cold incidence in the general population. Cold duration decreased modestly—by roughly 8% in adults, about 14% in children—but incidence (whether you catch a cold at all) remained unchanged.
That's the prophylactic verdict: megadosing doesn't prevent colds in most people.
Therapeutically—taking high doses after symptoms appear—the data shifts. The same meta-analysis found that when vitamin C was started within 24 hours of symptom onset, it reduced duration by roughly 19% in children and 8–14% in adults. That's clinically noticeable but not dramatic. In practical terms: if you normally have a 10-day cold, high-dose vitamin C might shorten it to 9 days. Worth doing? Perhaps. Life-changing? No.
Dosage: Where Pauling's Claims Meet Reality
Pauling recommended 3,000–10,000 mg daily as prophylaxis, with higher doses during illness. Modern studies typically use 200–2,000 mg daily for prevention and 1,000–2,000 mg taken repeatedly after symptom onset.
A critical finding: more is not better. The dose-response relationship is not linear. A 2021 study in Nutrients examining 18 trials found that 1,000–2,000 mg daily performed similarly to higher doses, with diminishing returns and increased risk of side effects (kidney stones, diarrhea, oxalate accumulation) at extreme intakes.
The recommended dietary allowance (RDA) for vitamin C is 75–90 mg daily for adults—far below what Pauling advocated. Most people in developed countries obtain this easily from diet. The leap to 2,000 mg daily is a 22–27 fold increase over requirement. The benefit, if it exists, is modest enough that the cost-benefit calculation becomes personal.
Who Actually Sees a Response?
One of the most overlooked findings in the vitamin C literature: response is population-dependent. A 2013 analysis found that people under intense physical or environmental stress—marathon runners, soldiers in cold weather, skiers—showed a roughly 50% reduction in cold incidence with megadose supplementation. The general desk-bound population? No reduction.
This makes mechanistic sense. Intense exercise and cold stress activate the adrenal axis and suppress immune function acutely. Vitamin C supports catecholamine metabolism and immune function under stress. If your immune system is already suppressed, additional vitamin C has substrate to work with. If your immune system is functioning normally, adding more substrate provides little advantage.
So the honest answer is: if you're training intensely, competing in endurance events, or exposed to sustained cold, megadose vitamin C (1,000–2,000 mg daily) shows evidence of modest protective effect. If you're sedentary or moderately active, the data doesn't support prophylactic megadosing.
The Plasma Saturation Problem
An underappreciated limitation of high-dose supplementation: human plasma vitamin C reaches saturation around 1,000–1,200 mg daily. Beyond this threshold, excess vitamin C is excreted in urine. You cannot achieve a dose-response curve beyond saturation.
Pauling assumed that more vitamin C in blood meant more immune benefit. Research on bioavailability—particularly work by Evans and colleagues on transporter kinetics—showed this assumption is false. Once plasma saturation is achieved, additional supplementation provides no additional concentration in immune tissues. The tablets you're swallowing are largely traveling to your kidneys.
This doesn't mean 1,000 mg is pointless. It means that taking 5,000 mg provides no additional benefit compared to 1,200 mg. Pauling's megadose framing was based on a misunderstanding of absorption kinetics.
Genetic Variation and Responders vs. Non-Responders
Emerging evidence suggests that variants in the GCLC gene (glutamate-cysteine ligase catalytic subunit) and vitamin C transporter genes (SVCT1, SVCT2) may predict response to supplementation. People with certain polymorphisms show enhanced intracellular vitamin C accumulation; others do not. A 2020 study in Nutrients found that genetic screening could identify responders to high-dose vitamin C supplementation with greater accuracy than phenotype alone.
This means some people genuinely do benefit from megadosing, while others are non-responders based on genetics. Population-level statistics hide this heterogeneity. The 8% average reduction in cold duration might represent 40% of the population experiencing 20% reduction and 60% experiencing no change, rather than everyone experiencing 8% reduction.
Practically, you won't know your own status without trying—or eventually, without genetic testing—but this explains why Pauling's anecdotal testimonials were genuine (he may have been a responder) while population studies show weak effects.
Interactions With Other Immune Factors
Vitamin C doesn't act in isolation. Sleep deprivation, zinc deficiency, low vitamin D, and chronic stress all suppress immune function. Megadose vitamin C cannot compensate for fundamental deficits in sleep or micronutrient status.
A 2019 study in FASEB Journal found that vitamin C supplementation only improved cold outcomes in people with adequate zinc status. Among zinc-deficient participants, vitamin C supplementation provided no benefit. This suggests that targeting the actual limiting micronutrient is more important than chasing megadoses of one nutrient.
Similarly, vitamin D insufficiency (below 20 ng/mL) blunts the immune response to cold viruses. Correcting vitamin D status may be more impactful than escalating vitamin C. The same applies to iron, selenium, and copper—all required for antiviral immune responses.
Timing and Administration: The Therapeutic Window
If you decide to use vitamin C for cold symptom management, timing is critical. The evidence is strongest when high doses are started within 24 hours of symptom onset. Starting on day three or four shows minimal benefit.
Additionally, the method matters. Oral supplementation at high doses (beyond 1,000–1,500 mg per dose) causes osmotic diarrhea in most people. Intravenous vitamin C—popular in functional medicine clinics—achieves higher plasma concentrations but at significant cost ($100–300 per infusion) and without substantial evidence of superiority over optimized oral dosing. A 2017 review in Critical Care found no high-quality evidence that IV vitamin C outperforms oral supplementation for viral respiratory infections in non-hospitalized populations.
Safety at Megadose Levels
Long-term supplementation above 2,000 mg daily carries documented risks. Kidney stone formation increases—particularly in men with personal or family history of stones. Oxalate accumulation can occur. High-dose vitamin C is metabolized to oxalate and excreted renally; in people with reduced kidney function or genetic susceptibility to hyperoxaluria, this poses genuine risk.
Additionally, in people with hemochromatosis or iron overload, vitamin C increases iron absorption, potentially worsening organ damage. The narrative that "excess vitamin C is harmless because it's water-soluble" is outdated; modern pharmacokinetic research shows meaningful safety concerns at megadose levels over years of use.
Short-term use (during cold season, or after symptom onset) is far safer than year-round megadosing, with lower cumulative exposure.
What Actually Works for Cold Prevention
If your goal is reducing cold incidence, the evidence prioritizes other interventions: sleep (7–9 hours nightly reduces cold risk by approximately 65%), hand hygiene, avoiding touching your face, and managing stress. These are unglamorous but consistently more effective than any supplement.
For athletes and people in extreme environments, moderate vitamin C supplementation (1,000–1,200 mg daily) combined with adequate zinc, vitamin D, and sleep provides a more rational approach than Pauling-level megadosing.
The Remaining Uncertainty
Vitamin C megadosing remains genuinely controversial not because the evidence is absent but because it's modest and heterogeneous. Pauling was right that vitamin C matters for immune function; he was wrong that megadoses prevent colds in the general population. He was right that some people benefit; he was wrong to assume everyone does.
The honest verdict: if you're under intense physical stress or cold exposure, 1,000–1,500 mg daily of vitamin C may reduce cold risk by 30–50%. If you're otherwise healthy and sedentary, the evidence doesn't support prophylactic megadosing. If you catch a cold, taking 1,000 mg doses at the first symptom may shorten duration by 1–2 days—a modest benefit worth weighing against GI side effects and cost.
What remains unknown: whether genetic testing will ever justify personalized megadose protocols, whether certain vitamin C formulations (ascorbic acid vs. mineral ascorbates) perform differently, and whether combination protocols with quercetin, zinc, and other immune-supporting compounds outperform vitamin C alone.
